Pfizer agrees to acquire Baxter’s vaccines business for $635m
Under the deal, Pfizer will acquire a portion of Baxter’s facility in Orth, Austria, and will also have access to Baxter’s meningitis vaccine, NeisVac-C, and its encephalitis vaccine,
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Research shows that cannabinoids have medical application for a range of conditions as varied as epilepsy, glaucoma, osteoporosis, anorexia, Alzheimer’s disease and pain treatment. Following the recent success